A new milestone for Monthey-based Ninsun Biotech, a startup incubated by the Ark Foundation and hosted at the BioArk technology site, underscores the strength of the Valais life sciences innovation ecosystem.
Ninsun Biotech has been awarded Venture Kick Stage 1, a recognition that reinforces its mission to improve lung cancer management through earlier and more precise clinical intervention.
The company’s test, already clinically validated on more than 300 patients, measures the true aggressiveness of tumors at diagnosis. This data empowers oncologists to tailor treatment strategies when they can have the greatest impact on patient outcomes.
Building on this success, Ninsun Biotech is now working to predict immunotherapy response before treatment begins. A multicenter clinical study is underway, with completion targeted for the end of 2026. The objective is compelling: to avoid ineffective therapies, unnecessary toxicity, and lost time in the fight against cancer.
“We are proud to have earned this recognition,” shared Sylvain Gnaho, CEO of Ninsun Biotech. “It strengthens our belief that to fight lung cancer effectively, we must intervene earlier and smarter.”
Backed by Venture Kick, Ninsun Biotech is now seeking to accelerate patient access to its diagnostic technology and invites investors eager to transform the future of cancer care to join this journey.
➡️ Learn more about Ninsun Biotech’s work: https://lnkd.in/e4shqrvV
